We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

DRG Group Presents New Analyzer and ELISAs at Dubai Lab Exhibition

By LabMedica International staff writers
Posted on 08 Feb 2017

Image: The DRG:HYBRiD-XL random access analyzer (Photo courtesy of DRG).

Image: The DRG:HYBRiD-XL random access analyzer (Photo courtesy of DRG).

The DRG Group, a leading medical diagnostic and laboratory equipment supplier, demonstrated its fully automated random access analyzer, DRG:HYBRiD-XL, along with its newest ELISAs, at MEDLAB 2017, the world’s largest laboratory exhibition and congress in the Middle East.

The DRG:HYBRiD-XL is a fully automated, continuous access analyzer that allows the simultaneous measurement of immunoassays and clinical chemistry parameters, including turbidimetric tests in one sample. It allows medical practitioners to carry out up to 40 tests of different types or 40 times of the same test, or up to 20-patient samples over a wide range of pre-packaged tests to serve different specialties.

DRG also highlighted its newest ELISAs such as Salivary Progesterone HS (High Sensitivity) ELISA, DHT-optimized and Hepcidin 25 (bioactive) HS ELISA kit at MEDLAB 2017. The company’s saliva diagnostics products offer several benefits such as non-invasive sampling, measurement of the free (unbounded) fraction of steroids, and much higher diagnostic relevance with reproducible and reliable results, compared to serum analytics. DRG’s new Salivary Progesterone HS ELISA is calibrated against mass spectrometry, which is considered as gold standard in saliva diagnostics.

Visit expo >

Platinum Member

Automated Coagulation Analyzer

Hemolumi H6

New

Gold Member

Blood-Based Protein Biomarker Solution for Alzheimer's Disease

BG-DTi2000.

New

Portable POCT Blood Gas Analyzer

BD100

Manual Pipetting Aid

Pipette Controllers macro

Latest MEDLAB 2017 News

Channels

Clinical Chemistry

view channel

Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

New Chairside Oral Swab Test Could Guide Biopsy Decisions in Oral Cancer

Oral squamous cell carcinoma can be difficult to triage at the point of care, resulting in frequent biopsies of lesions that ultimately prove benign. Limited access to pathology services in many communities... Read more

$Image: New findings show that measuring a broader panel of blood proteins can improve Alzheimer\'s disease staging (Image Credit: iStock)$

Multi-Protein Blood Test Improves Staging of Alzheimer’s Disease

Alzheimer’s disease begins years before dementia develops, as amyloid plaques and tau pathology progressively damage neurons. Diagnosis has traditionally relied on cognitive decline, while biomarker testing... Read more

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more

Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Liquid Biopsy Combines Multiple Signals for Cancer Detection in a Single Analysis

Detecting and monitoring cancer often requires repeated tissue biopsies, which are invasive and not always feasible. Liquid biopsy offers a less invasive way to track disease over time, but many assays... Read more

Newborn Screening Program Adds Spinal Muscular Atrophy Testing Across England

Spinal muscular atrophy is a rare but serious genetic condition that can rapidly impair motor function in infants and, in severe cases, compromise breathing and swallowing. Detecting the disorder before... Read more

Hematology

view channel

New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome

Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more

Ultra-Portable Device Enables Finger-Prick Blood Testing at Home

Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read more

Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam

Complete blood count (CBC) results underpin pediatric evaluation for anemia, infection, inflammation, and platelet disorders. Yet laboratories in Vietnam have largely relied on reference intervals derived... Read more

Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma

Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read more

Immunology

view channel

Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis

Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more

Image: The findings highlight the potential of blood-based immune profiling to provide a more comprehensive picture of how patients respond to immunotherapy. (Image Credit: Adobe Stock)

Immune Cell Blood Test May Predict Melanoma Immunotherapy Response

Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read more

Study Reveals Viral Protein Driving COVID-19-Related Vascular Injury

Lingering symptoms after acute COVID-19 infection remain a clinical challenge, with many patients experiencing fatigue, cognitive problems, and cardiovascular complications months later.... Read more

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Microbiology

view channel

Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.

Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read more

Plasma Cell-Free DNA Test Enables Earlier Diagnosis of Invasive Fungal Infections

Invasive fungal infections disproportionately affect immunocompromised patients, while diagnostic delays can contribute to substantial morbidity and mortality. Existing methods often depend on invasive... Read more

Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel

Image: The fine-tuned model predicted seven outputs using whole slide images (WSIs). (Abadh K. Chaurasia et al, The American Journal of Pathology (2026). DOI: 10.1016/j.ajpath.2026.05.008)

AI Uses H&E Slides to Predict Key Biomarkers Across 32 Cancers

Molecular profiling is essential for characterizing solid tumors, but many laboratories still rely on separate genetic assays to detect alterations such as TP53 mutations. These workflows can be resource-intensive... Read more

AI Tool Identifies Slide Artifacts to Speed Digital Pathology Diagnosis

Pathology laboratories face growing case volumes, staffing pressures, and increasing diagnostic complexity that can delay results. At the same time, whole-slide images may contain quality defects such... Read more

Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more

AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer

Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more

Technology

view channel

Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results

Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more

Training Device Improves Accuracy of Pooled Molecular Diagnostics

High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more

New CE-Certified Software Advances Whole-Genome Cancer Testing

European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more

National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care

Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read more

Industry

view channel

Collaboration Supports Global ADC Development with AI-Powered Tissue Analysis

Selecting patients for antibody-drug conjugates (ADCs) increasingly requires broader tissue context, as target expression alone may not fully explain therapeutic response. Laboratories and translational... Read more

Image: Professor David Brettle, Chief Scientific Officer at Leeds Teaching Hospitals NHS Trust with a pathology slide showing the TANGO technology (Photo courtesy of Leeds Teaching Hospitals NHS Trust)

Standardized Staining Technology Advances Digital Pathology Workflows

Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more

Global Testing Service Advances Leukemia MRD Monitoring

KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more

Ultrasensitive MRD Assay Gains Medicare Coverage for Immunotherapy and Breast Cancer Monitoring

Patients with late-stage solid tumors and breast cancer often require repeated monitoring to assess recurrence risk and treatment response. Minimal residual disease (MRD) testing is intended to detect... Read more